{"id":16674,"date":"2024-07-23T22:55:00","date_gmt":"2024-07-23T12:55:00","guid":{"rendered":"https:\/\/doseme-rx.com\/?p=16674"},"modified":"2025-01-22T06:12:46","modified_gmt":"2025-01-21T20:12:46","slug":"doseme-expands-licensing-agreement-with-dot-lib","status":"publish","type":"post","link":"https:\/\/doseme-rx.com\/de\/news-media\/article\/doseme-expands-licensing-agreement-with-dot-lib","title":{"rendered":"DoseMe Expands Licensing Agreement with Dot.lib"},"content":{"rendered":"\n

Partnership continues to drive adoption of precision dosing that achieves improved healthcare outcomes, operational efficiency for clinical pharmacists and physicians, and decreased costs<\/em><\/p>\n\n\n\n

Jupiter, FL \u2013 July 23, 2024<\/p>\n\n\n\n

DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced it has expanded its agreement with Dot.lib<\/a> as its reseller and distribution partner in Mexico, Costa Rica, Panama, Colombia, Chile, Argentina, Uruguay, Paraguay, Brazil and other Latin America countries.<\/p>\n\n\n\n

Since 1991, DotLib has been a leading provider of scientific healthcare information solutions, dedicated to empowering academic, corporate, and government institutions in Latin America and Iberia with access to high-quality digital resources.<\/p>\n\n\n\n

\u201cThe two companies have been partnered since 2019 and the new agreement will help foster education and growth of therapeutic drug monitoring (TDM) that has evolved as an important tool,\u201d said Paul Edwards, CEO at DoseMe. \u201cOur real-world data proves the transition from trough dosing to precision dosing of antibiotics in individual patients with infections, particularly in critically ill patients, contributes to improved information for clinicians, even in the highest risk cases, which directly improves the overall patient journey.\u201d<\/p>\n\n\n\n

Results reported in the study<\/a> „Switching Vancomycin Monitoring From Trough Concentration to Area Under the Curve Estimation by Bayesian Forecasting: A Short Communication on a Cost-Benefit Study in Resource-Limited Settings“<\/em>, by Jo\u00e3o Paulo M. Telles, MD, PhD, Infectious Diseases Specialist, A.C. Camargo Cancer Center<\/a> and recently published in Therapeutic Drug Monitoring Journal, show how commercial vancomycin Bayesian forecasting\u2013based protocol presents important cost-benefit outcomes, even in resource-limited settings, as decreased laboratory expenditures can overcome software costs.<\/p>\n\n\n\n

\u201cIn the area of precision dosing, we have partnered with DoseMe to deliver best-in-class software and services to help enhance clinical pharmacist and physician efficiency, reduce healthcare costs and, ultimately, improve patient outcomes,\u201d said Humberto Marcolini, Regional Sales Manager for Portugal and Spain at Dot.lib. \u201cWe can easily demonstrate why DoseMeRx is the industry-leading, model-informed precision dosing platform and renewing the agreement is what is right for us and the healthcare organizations we serve now and in the future.\u201d<\/p>\n\n\n\n

Dot.lib provides an extensive range of selected databases, e-journals, e-books, and other digital solutions from premier providers worldwide, ensuring that physicians, pharmacists, nurses and other healthcare professionals have access to the most relevant research, tools and technology in their respective fields.<\/p>\n\n\n\n

About DoseMe<\/h3>\n\n\n\n

DoseMe combines smart technology with science, leveraging clinically-validated PK\/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https:\/\/doseme-rx.com\/success-stories<\/a><\/p>\n\n\n

\r\n \r\n
\r\n\t

Demo anfordern<\/h2>\r\n\t

Sehen Sie, wie einfach DoseMeRx zu bedienen und in Ihren Arbeitsalltag zu integrieren ist.<\/p>\n

Fordern Sie unten eine Demo an. Sie k\u00f6nnen uns auch anrufen unter +1 (832) 358-3308 oder eine E-Mail an hello@dosemehealth.com<\/a> senden.<\/p>\n<\/div>\t\t\r\n\r\n